Reaction
Macule reporting signals
As of the last recalculation, Macule appears in 2,739 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is SECUKINUMAB (PRR 48.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Secukinumab | 747 | 48.0 | 48.2 |
| Terbinafine Hydrochloride | 17 | 14.6 | 14.7 |
| Rabeprazole | 36 | 12.5 | 12.5 |
| Clobetasol Propionate Ointment Usp, 0.05% | 15 | 11.1 | 11.1 |
| Clobetasol Propionate | 15 | 11.1 | 11.1 |
| Pyrazinamide | 10 | 8.1 | 8.1 |
| Ketoconazole | 17 | 7.5 | 7.5 |
| Ketoconazole Foam | 14 | 7.2 | 7.2 |
| Ketoconazole Cream, 2% | 14 | 7.2 | 7.2 |
| Isoniazid | 14 | 6.6 | 6.6 |
| Phenytoin | 17 | 6.2 | 6.2 |
| Mupirocin | 11 | 6.2 | 6.2 |
| Mupirocin Calcium | 11 | 6.1 | 6.1 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 18 | 5.9 | 5.9 |
| Dextrose | 10 | 5.8 | 5.8 |
| Dextrose Monohydrate | 10 | 5.7 | 5.7 |
| Ceftriaxone Sodium | 28 | 5.6 | 5.6 |
| Carbamazepine | 46 | 5.3 | 5.3 |
| Rifampicin | 7 | 5.3 | 5.3 |
| Minocycline | 8 | 5.2 | 5.2 |
| Ceftriaxone | 22 | 5.1 | 5.1 |
| Vemurafenib | 8 | 5.1 | 5.1 |
| Canakinumab | 7 | 4.9 | 4.9 |
| Meropenem | 20 | 4.8 | 4.8 |
| Imatinib | 11 | 4.8 | 4.8 |
| Everolimus Tablets | 10 | 4.5 | 4.5 |
| Niraparib | 13 | 4.5 | 4.5 |
| Triamcinolone Acetonide | 18 | 4.5 | 4.5 |
| Miconazole Nitrate | 5 | 4.4 | 4.4 |
| Rifampin | 8 | 4.2 | 4.2 |
| Crisaborole | 5 | 4.0 | 4.0 |
| Dofetilide | 5 | 3.6 | 3.6 |
| Etanercept | 238 | 3.2 | 3.2 |
| Apremilast | 57 | 3.0 | 3.0 |
| Vismodegib | 3 | 2.6 | 2.6 |
| Abaloparatide | 5 | 1.3 | 1.3 |
| Pomalidomide | 15 | 1.1 | 1.1 |
| Evolocumab | 18 | 0.8 | 0.8 |